Pyrosequencing Analysis of MGMT Promoter Methylation in Meningioma

Cancer Genomics Proteomics. 2018 Sep-Oct;15(5):379-385. doi: 10.21873/cgp.20096.


Background: Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is a well-established predictor of response to the DNA-alkylating agent temozolomide in patients with glioblastoma.

Materials and methods: Pyrosequencing analysis was used to determine the MGMT promoter methylation status in 61 meningiomas, to clarify whether it might have a predictive role.

Results: Only two tumors (3%) had a mean methylation frequency higher than the cut-off value of 10% for the four CpG sites examined.

Conclusion: The methylation of the MGMT promoter is uncommon, or occurs at a low frequency in meningiomas. There is no convincing rationale to test such tumors for their MGMT methylation status in a clinical setting.

Keywords: MGMT promoter; Meningioma; methylation; predictive value; pyrosequencing.

MeSH terms

  • Adult
  • Aged
  • DNA Methylation / genetics*
  • DNA Modification Methylases / genetics*
  • DNA Repair Enzymes / genetics*
  • Female
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Male
  • Meningioma / genetics*
  • Meningioma / pathology
  • Middle Aged
  • Promoter Regions, Genetic / genetics
  • Sequence Analysis, DNA
  • Tumor Suppressor Proteins / genetics*


  • Tumor Suppressor Proteins
  • DNA Modification Methylases
  • MGMT protein, human
  • DNA Repair Enzymes